Search clinical trials for: Apatinib, VEGFR2 antibody

Total 5089 results

Osaka University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy

Age Related Macular Degeneration | Neovascular Maculopathy

Japan
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Japanese Foundation for Cancer Research
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Multiple Peptide Vaccine to Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Breast Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Gastric Cancer

Japan
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Colon Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Ruijin Hospital

Recruiting

BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS)

Sarcoma

China
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
University of Florida

Withdrawn

Explore the Synergy of Combination TKI Therapy

Healthy Volunteers
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Pancreatic Cancer

Japan
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Breast Cancer | Triple-Negative Breast Cancer

China
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Bristol-Myers Squibb

Withdrawn

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Pusan National University Hospital

Available

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Chronic Myeloid Leukemia
Tianjin Medical University Cancer Institute and...

Completed

Chemotherapy Combined With Apatinib and PD-1 Antibody

Gastric Cancer

China
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Leukemia, Chronic Myeloid

Italy
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Boehringer Ingelheim

Completed

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Breast Neoplasms

United States, Brazil, Colombia, Peru
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Mayo Clinic
National Cancer Institute (NCI)

Completed

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFR

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Solid Tumor

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Huazhong University of Science and Technology

Unknown

PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT

HCC

China
Fujian Cancer Hospital

Unknown

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
Liang Peng
Guangzhou Virotech Pharmaceutical Co., Ltd.

Unknown

IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC

Advanced/Metastatic Hepatocellular Carcinoma
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Beijing Chest Hospital

Unknown

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Ruijin Hospital

Active, not recruiting

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (PROACH)

Pulmonary Metastases | Osteosarcoma | Apatinib

China
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Bristol-Myers Squibb

Terminated

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Leukemia, Myeloid, Chronic

Sweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States

Search clinical trials for: Apatinib, VEGFR2 antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations